^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | MK-2206 (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
Excerpt:
We examined the effects of MK2206 on thyroid cancer cells with respect to the genotypes of the PI3K/Akt pathway....The SW1736 cell, lacking mutations in the PI3K/Akt pathway, had minimal response to MK2206, but transfection with exogenous PIK3CA mutants, PIK3CA H1047R and E545K, significantly increased its sensitivity to MK2206.
DOI:
10.1210/jc.2010-2644
